European equity markets were broadly subdued as traders balanced corporate earnings news against rapidly changing geopolitical headlines in the Middle East. The pan-European STOXX 600 posted a modest gain of 0.07%, trading near 657.27 by 0857 GMT and touching an intraday record level after closing at an all-time peak in the previous session.
Market participants were responding to mixed signals from the region following a rocket attack by Yemen’s Iran-aligned Houthi group on a Saudi oil tanker in the Red Sea. The incident helped push Brent crude futures higher, with prices rising 1.2% to trade around $80.39.
Meanwhile, investors were also noting comments that U.S. officials reported productive, day-long talks with Iran, but market reaction suggested traders are prioritising corporate fundamentals over geopolitical narratives for the moment. "By and large, they (markets) are just discounting political narratives, geopolitical narratives," said Kathleen Brooks, research director at XTB. "Corporate fundamentals are the key theme that is driving stocks right now."
Sectors that benefited included energy and mining. Energy shares advanced about 0.6% in line with higher oil prices. Mining stocks led sector gains, up roughly 1.4%, as gold climbed to a one-month high amid a softer dollar.
Several individual company results influenced the market tone. Siemens Energy rose 1.3% after reporting a record third-quarter performance, supported by stronger demand from AI data centre projects and power plant contracts in the Middle East. Glencore outperformed after reporting an 86% jump in first-half earnings and beat forecasts, with the stock rising 3.3%.
In contrast, bank shares were under pressure, with the banking sector down about 0.9%. HSBC was a notable decliner, falling 3.5% after its results the previous day. Novo Nordisk slipped 3.8% despite raising its full-year sales and profit outlook; investors focused on a narrow sales miss for its new Wegovy pill and a trial setback for its next-generation obesity treatment, CagriSema. The Danish drugmaker is attempting to regain ground from Eli Lilly in the expanding obesity-drug market, but the share price has retreated as competition and cooling growth expectations weighed on valuation.
Not all pharmaceutical-related names lagged: Sandoz climbed 7.4% to top the benchmark after reporting a 9% increase in second-quarter net sales, driven by biosimilars growth as patents expire on established medicines.
The session illustrated a market environment where commodity-sensitive sectors - energy and mining - found support from rising oil and gold, while financials and certain healthcare names reacted to company-specific disappointments. Overall market movement remained modest as traders absorbed corporate updates and tracked geopolitical developments.